Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV (Janssen-Cilag), a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI). The CHMP has confirmed its previous negative opinion on the use of ceftobiprole for the treatment of cSSTI.

Read the full story here

Medline Industries, Inc. has introduced Remedy® with Phytoplex™, a highly advanced skin care system for sensitive and damaged skin. A blend of the latest advances in biotechnology and molecular biology, Remedy® with Phytoplex™ is specifically designed and developed to nourish and soothe the skin, act as a structural moisturizer and help protect sensitive skin from free radical damage.

Read the full story here

NanoVibronix has announced that following its initial success with the first generation PainShield device for pain therapy, especially for the severe pain associated with Trigeminal Neuralgia, NanoVibronix presents its second generation PainShield with additional features for the therapy of chronic pain and wounds. PainShield is a small, portable device that produces low frequency, low intensity ultrasonic waves for healing of soft tissue such as tendon, chronic wounds and neuropathic pain.

Read the full story here

New Look Skin Care Ltd. has  introduced the latest treatment for stretch marks available in town, Carboxytherapy—a Carbon dioxide therapy that has been applied to the treatment of stretch marks, cellulite, and hypertrophic scars with impressive results. New Look Skin Laser Centre provides this facility at all the seven centers in Delhi and five other centers in the NCR region.

Read the full story here

A study done by the FDA indicated that the Vitamin A used in almost half of the roughly 500 sunscreens on the market may actually increase the growth of skin cancer. Dr. Kim Gittere Abson, a dermatologist at the Polyclinic in Seattle, “So this is a study that was conducted by the FDA that looked at mice using a form of Vitamin A called Retinal Palmitate.” “And in the mice, that were just treated with the Vitamin A, versus the ones that were not, there was a 21% increase in skin cancer in those mice.”

Onset Therapeutics has announced a publication in the June issue of the Journal of Drugs in Dermatology summarizing the results of a study assessing the effect of BenzEFoam™ (benzoyl peroxide) 5.3% Emollient Foam compared to a commercially available prescription benzoyl peroxide 8% cleanser in reducing the level of P. acnes counts in patients with significant P. acnes colonization on their backs.

Read the full story here

A new study by Loyola University Health System researchers could lead to alternative treatments that would shrink skin cancer tumors with drugs. The drugs would work by turning on a gene that prevents skin cells from becoming cancerous. More than 1 million people in the United States are diagnosed with skin cancer each year. In the new study, researchers examined a type of skin cancer, called squamous cell carcinoma.

For the full story, Click Here

Pfizer Inc and Debiopharm Group™ have announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for its worldwide commercialization.

For the full story, Click Here

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology – Head and Neck Surgery. CRS is a debilitating form of sinusitis that can lead to significant physical symptoms as well as substantial functional and emotional impairment.

For the full story, Click Here

Cardium Therapeutic has announced that its wholly-owned subsidiary, Tissue Repair Company, submitted a 510(k) premarket notification filing with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its Excellagen(TM) product candidate based on positive data from the Company’s recently completed Phase 2b Matrix clinical study. ExcellagenXL(TM) and ExcellagenFX(TM) are advanced wound care management medical devices comprising customized collagen protein-based topical gels designed for use by health care professionals for patients with dermal wounds.

The the full story, Click Here